(0.33%) 5 117.04 points
(0.33%) 38 365 points
(0.37%) 15 987 points
(-0.94%) $83.06
(5.56%) $2.03
(0.34%) $2 355.10
(0.44%) $27.66
(4.04%) $959.35
(-0.25%) $0.932
(-0.42%) $10.98
(-0.58%) $0.796
(1.69%) $93.43
@ $0.740
発行日: 14 2月 2024 @ 02:37
リターン: 1 734.52%
前回のシグナル: 2月 14 - 01:13
前回のシグナル:
リターン: 0.58 %
Live Chart Being Loaded With Signals
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies...
Stats | |
---|---|
本日の出来高 | 1.88M |
平均出来高 | 726 115 |
時価総額 | 284.31M |
EPS | $0 ( 2024-03-14 ) |
次の収益日 | ( $-3.10 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.980 |
ATR14 | $0.0450 (0.33%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-05 | Hirsch Susan B | Buy | 5 000 | Stock Option |
2024-02-05 | Wiinberg Ulf | Buy | 5 000 | Stock Option |
2024-02-05 | Corvese Brian | Buy | 15 000 | Stock Option |
2024-02-05 | Jeynes-ellis Allison M | Buy | 5 000 | Stock Option |
2024-02-05 | Wright Timothy | Buy | 7 500 | Stock Option |
INSIDER POWER |
---|
100.00 |
Last 98 transactions |
Buy: 11 279 188 | Sell: 367 647 |
ボリューム 相関
Agenus Inc 相関
10 最も正の相関 | |
---|---|
BTTX | 0.967 |
OMCL | 0.963 |
CDMO | 0.962 |
SCPH | 0.961 |
SVRE | 0.957 |
SILK | 0.957 |
OMER | 0.956 |
LIFE | 0.951 |
LITM | 0.951 |
CFRX | 0.951 |
10 最も負の相関 | |
---|---|
FRSG | -0.974 |
IVCB | -0.973 |
TBSA | -0.97 |
LEGA | -0.968 |
CPAQ | -0.968 |
AHRN | -0.967 |
LGAC | -0.967 |
FTPA | -0.967 |
ACQR | -0.966 |
HORI | -0.966 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Agenus Inc 相関 - 通貨/商品
Agenus Inc 財務諸表
Annual | 2023 |
収益: | $156.31M |
総利益: | $139.62M (89.32 %) |
EPS: | $-0.690 |
FY | 2023 |
収益: | $156.31M |
総利益: | $139.62M (89.32 %) |
EPS: | $-0.690 |
FY | 2022 |
収益: | $98.02M |
総利益: | $-99.24M (-101.24 %) |
EPS: | $-0.960 |
FY | 2021 |
収益: | $295.67M |
総利益: | $113.59M (38.42 %) |
EPS: | $-0.110 |
Financial Reports:
No articles found.
Agenus Inc
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。